Climb Bio Offers Compelling, Data-Rich H2 With Multiple Near-term Catalysts Across Two Programs, RBC Says

MT Newswires Live08-03

Climb Bio (CLYM) offers a compelling, data-rich H2, with several near-term catalysts across two differentiated programs in highly unmet need B-cell mediated diseases, RBC Capital Markets said in a Monday research note.

RBC said that the proof-of-concept data for the company's Budoprutug anti-CD19 monoclonal antibody in primary membranous nephropathy from low dose has demonstrated early signals of efficacy, with recent immune thrombocytopenia data further de-risking the safety profile, suggesting Budoprutug can be dosed even higher.

RBC said it sees out-year sales of about $700 million from Budoprutug across indications of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.

RBC further said that the company's "CLYM116 anti-APRIL mechanism is de-risked" reflecting clinical and commercial validation, with sweeper Fc engineering potentially placing it competitively in the crowded IgA nephropathy market.

RBC initiated its coverage on the company's stock with an outperform rating and $23 per share price target.

Price: 11.40, Change: -0.50, Percent Change: -4.20

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656308309?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 23:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656308309","market":"hk","top_or_hot":-1,"title":"Climb Bio Offers Compelling, Data-Rich H2 With Multiple Near-term Catalysts Across Two Programs, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a> (CLYM) offers a compelling, data-rich H2, with several near-term catalysts across two differentiated programs in highly unmet need B-cell mediated diseases, RBC Capital Markets said in a Monday research note.</p><p>RBC said that the proof-of-concept data for the company's Budoprutug anti-CD19 monoclonal antibody in primary membranous nephropathy from low dose has demonstrated early signals of efficacy, with recent immune thrombocytopenia data further de-risking the safety profile, suggesting Budoprutug can be dosed even higher.</p><p>RBC said it sees out-year sales of about $700 million from Budoprutug across indications of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.</p><p>RBC further said that the company's \"CLYM116 anti-APRIL mechanism is de-risked\" reflecting clinical and commercial validation, with sweeper Fc engineering potentially placing it competitively in the crowded IgA nephropathy market.</p><p>RBC initiated its coverage on the company's stock with an outperform rating and $23 per share price target.</p><p>Price: 11.40, Change: -0.50, Percent Change: -4.20</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Climb Bio Offers Compelling, Data-Rich H2 With Multiple Near-term Catalysts Across Two Programs, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClimb Bio Offers Compelling, Data-Rich H2 With Multiple Near-term Catalysts Across Two Programs, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-03 23:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a> (CLYM) offers a compelling, data-rich H2, with several near-term catalysts across two differentiated programs in highly unmet need B-cell mediated diseases, RBC Capital Markets said in a Monday research note.</p><p>RBC said that the proof-of-concept data for the company's Budoprutug anti-CD19 monoclonal antibody in primary membranous nephropathy from low dose has demonstrated early signals of efficacy, with recent immune thrombocytopenia data further de-risking the safety profile, suggesting Budoprutug can be dosed even higher.</p><p>RBC said it sees out-year sales of about $700 million from Budoprutug across indications of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.</p><p>RBC further said that the company's \"CLYM116 anti-APRIL mechanism is de-risked\" reflecting clinical and commercial validation, with sweeper Fc engineering potentially placing it competitively in the crowded IgA nephropathy market.</p><p>RBC initiated its coverage on the company's stock with an outperform rating and $23 per share price target.</p><p>Price: 11.40, Change: -0.50, Percent Change: -4.20</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLYM","symbol_name":"CLIMB BIO INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656308309","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656308309","pubTimestamp":1785771618,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Climb Bio  offers a compelling, data-rich H2, with several near-term catalysts across two differentiated programs in highly unmet need B-cell mediated diseases, RBC Capital Markets said in a Monday research note.RBC said that the proof-of-concept data for the company's Budoprutug anti-CD19 monoclonal antibody in primary membranous nephropathy from low dose has demonstrated early signals of efficacy, with recent immune thrombocytopenia data further de-risking the safety profile, suggesting Budoprutug can be dosed even higher.RBC said it sees out-year sales of about $700 million from Budoprutug across indications of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.RBC further said that the company's \"CLYM116 anti-APRIL mechanism is de-risked\" reflecting clinical and commercial validation, with sweeper Fc engineering potentially placing it competitively in the crowded IgA nephropathy market.RBC initiated its coverage on the company's stock with an ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLYM":"CLIMB BIO INC","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"加拿大皇家银行表示，Climb Bio 通过两个项目提供引人注目的、数据丰富的 H2 和多种近期催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":1},"content_text":"Climb Bio (CLYM) offers a compelling, data-rich H2, with several near-term catalysts across two differentiated programs in highly unmet need B-cell mediated diseases, RBC Capital Markets said in a Monday research note.RBC said that the proof-of-concept data for the company's Budoprutug anti-CD19 monoclonal antibody in primary membranous nephropathy from low dose has demonstrated early signals of efficacy, with recent immune thrombocytopenia data further de-risking the safety profile, suggesting Budoprutug can be dosed even higher.RBC said it sees out-year sales of about $700 million from Budoprutug across indications of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.RBC further said that the company's \"CLYM116 anti-APRIL mechanism is de-risked\" reflecting clinical and commercial validation, with sweeper Fc engineering potentially placing it competitively in the crowded IgA nephropathy market.RBC initiated its coverage on the company's stock with an outperform rating and $23 per share price target.Price: 11.40, Change: -0.50, Percent Change: -4.20","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656308309","isCrawlerRequest":true}